Literature DB >> 11085959

Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction.

A Mustafa1, S Nityanand, L Berglund, H Lithell, A K Lefvert.   

Abstract

BACKGROUND: Circulating immune complexes (CICs) and autoantibodies against oxidatively modified LDLs (oxLDLs) and cardiolipin occur in patients with atherosclerosis and myocardial infarction (MI). The ability of such CICs and antibodies to predict myocardial infarction (MI) was investigated in a prospective nested case-control study in which healthy 50-year-old men were followed for 20 years. METHODS AND
RESULTS: Two hundred fifty-seven men were included in the study, and 119 developed MI (39 died) between 50 and 70 years of age. One hundred thirty-eight randomly chosen men who did not develop MI up to 70 years of age served as controls. The prevalence of elevated levels of CICs and the concentration of CICs in men who developed MI were higher than in those who remained healthy. The concentration of CICs at age 50 was associated with a marked increased risk for MI, and this risk was independent of other conventionally recognized risk factors. There was a positive correlation between the levels of CIC and IgG antibodies to cardiolipin in men who developed MI. The level of IgG antibodies and the prevalence of elevated IgG and IgM antibodies to cardiolipin were higher in those who developed MI and had CICs than in those without CICs. Among men homozygous for C4 null alleles, those who developed MI had higher concentrations of CICs than did those who remained healthy.
CONCLUSIONS: This prospective study shows that CICs alone or in combination with autoantibodies against cardiolipin in healthy males at 50 years of age predict subsequent MI between the age of and 70 years.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085959     DOI: 10.1161/01.cir.102.21.2576

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

Review 1.  Oxidized low-density lipoprotein biomarkers in atherosclerosis.

Authors:  Sotirios Tsimikas
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

2.  Smoking and a complement gene polymorphism interact in promoting cardiovascular disease morbidity and mortality.

Authors:  G J Arason; J Kramer; B Blaskó; R Kolka; P Thorbjornsdottir; K Einarsdóttir; A Sigfúsdóttir; S T Sigurdarson; G Sigurdsson; Z Rónai; Z Prohászka; M Sasvári-Székely; S Bödvarsson; G Thorgeirsson; G Füst
Journal:  Clin Exp Immunol       Date:  2007-04-11       Impact factor: 4.330

Review 3.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

4.  The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology.

Authors:  Przemyslaw Kotyla
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

Review 5.  Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis.

Authors:  DeLisa Fairweather; Michelle A Petri; Michael J Coronado; Leslie T Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-03       Impact factor: 4.473

6.  Oxidation-specific biomarkers and risk of peripheral artery disease.

Authors:  Monica L Bertoia; Jennifer K Pai; Jun-Hee Lee; Adam Taleb; Michel M Joosten; Murray A Mittleman; Xiaohong Yang; Joseph L Witztum; Eric B Rimm; Sotirios Tsimikas; Kenneth J Mukamal
Journal:  J Am Coll Cardiol       Date:  2013-03-26       Impact factor: 24.094

7.  Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.

Authors:  Amir Ravandi; S Matthijs Boekholdt; Ziad Mallat; Philippa J Talmud; John J P Kastelein; Nicholas J Wareham; Elizabeth R Miller; Joelle Benessiano; Alain Tedgui; Joseph L Witztum; Kay-Tee Khaw; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2011-08-05       Impact factor: 5.922

8.  Effect of rheumatoid factor on mortality and coronary heart disease.

Authors:  Gunnar Tomasson; Thor Aspelund; Thorbjorn Jonsson; Helgi Valdimarsson; David T Felson; Vilmundur Gudnason
Journal:  Ann Rheum Dis       Date:  2009-07-23       Impact factor: 19.103

9.  Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study.

Authors:  C Turesson; A Jarenros; L Jacobsson
Journal:  Ann Rheum Dis       Date:  2004-03-29       Impact factor: 19.103

Review 10.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.